# Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer

Source: https://onco.cc/trials/symbiotic-lung-04/  
OnCo record `symbiotic-lung-04` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial testing PF-08634404 in non-small-cell lung cancer, now recruiting.

## Summary

Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer is a phase 2/3 interventional study registered as NCT07226999, led by Pfizer, and recruiting on the registry. Official title: A global phase 2/3 interventional study of PF-08634404 in combination with chemotherapy in participants with extensive stage small cell lung cancer. Planned enrolment is 550 participants (estimated). The study started in 2025-12-09 and primary completion is expected in 2030-06-14. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Also known as: Symbiotic-Lung-04
- Tags: ctgov-ingest
- Registry id: NCT07226999
- Phase: 2/3
- Setting: A global phase 2/3 interventional study of PF-08634404 in combination with chemotherapy in participants with extensive stage small cell lung cancer
- Sponsor: Pfizer
- Enrolled: 550

## Sources

- ClinicalTrials.gov NCT07226999: https://clinicaltrials.gov/study/NCT07226999

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [PF-08634404](https://onco.cc/drugs/pf-08634404/)
- companies: [Pfizer (incl. Seagen)](https://onco.cc/companies/pfizer/)

---
JSON: https://onco.cc/api/v1/entities/symbiotic-lung-04.json